Risk Factors and Outcomes after Surgery for Malignant Neoplasm of the Parotid Gland: An ACS-NSQIP Study
Knoedler L, Knoedler S, Hoch C, Safi A, Wollenberg B, Alfertshofer M, Pomahac B, Kauke-Navarro M, Clune J. Risk Factors and Outcomes after Surgery for Malignant Neoplasm of the Parotid Gland: An ACS-NSQIP Study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2024 PMID: 39448324, DOI: 10.1016/j.bjps.2024.09.067.Peer-Reviewed Original ResearchBlood urea nitrogenRisk factorsRenal failureParotid glandMalignant neoplasmsAmerican College of Surgeons National Surgical Quality Improvement Program databaseSurgeons National Surgical Quality Improvement Program databaseAssociated with higher creatinineNational Surgical Quality Improvement Program databaseMicrosurgical proceduresPre-operative risk factorsQuality Improvement Program databaseRisk of postoperative adverse eventsBlood urea nitrogen levelsHigher ASA classPostoperative adverse eventsOccurrence of complicationsPost-surgical outcomesTumor resectionComplication rateFlap surgeryPostoperative outcomesACS-NSQIPASA classHigher creatinineAdvancements in facial implantology: a review of hydroxyapatite applications and outcomes
Kauke-Navarro M, Knoedler L, Knoedler S, Safi A. Advancements in facial implantology: a review of hydroxyapatite applications and outcomes. Frontiers In Surgery 2024, 11: 1409733. PMID: 39092153, PMCID: PMC11291363, DOI: 10.3389/fsurg.2024.1409733.Peer-Reviewed Original ResearchFacial skeletal reconstructionLong-term safetySkeletal reconstructionFacial balanceTumor resectionCraniofacial surgeryAesthetic resultsFacial implantsReconstructive surgeryWeb of Science databasesInclusion criteriaPatient outcomesPatient satisfactionPatientsImplant integrationSystematic reviewSurgeryFacial reconstructionHAP implantsOutcomesGoogle ScholarScience databasesEfficacyHydroxyapatite applicationImplantationFrom standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner V, Safi A, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases. Frontiers In Immunology 2024, 15: 1276306. PMID: 38715609, PMCID: PMC11074450, DOI: 10.3389/fimmu.2024.1276306.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHead and neck cancerBreast cancerMonoclonal antibodiesCheckpoint inhibitorsSkin cancerReconstructive surgeryNon-surgical treatment strategiesProlonged progression-free survivalSuboptimal treatment plansProgression-free survivalNon-surgical therapySurgical tumor resectionImpaired patient outcomeStandardized treatment algorithmSurgical therapy planningAnti-cancer strategyUnresectable tumorsConventional chemotherapyRemission rateTumor resectionCurative therapyTargeted therapyNeck cancerOncology cases